Saturday 17 October 2026
Export HAE’s income statement to Excel — free account
Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
118.28
3.01
−2.48%
Follow HAE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
19.47% | 19.30% | 12.03% | 11.20% | |
Piotroski F-Score |
7 | 7 | 6 | 7 | |
| 6.77% | 6.99% | 4.02% | 3.99% | ||
ROIC |
10.30% | 10.69% | 5.53% | 5.62% | |
Return on Tangible Assets |
26.12% | 25.03% | 11.34% | 11.31% | |
Average Days of Receivables |
56.92 | 54.19 | 59.33 | 58.33 | |
Free Cash Flow per Share |
5.45 | 6.65 | 5.55 | 6.45 | |
Free Cash Flow |
259.20 | 311.38 | 261.82 | 292.53 | |
Capital Expenditures |
(29.84) | (27.46) | (31.40) | (35.62) | |
| Other line items | |||||
Cash ROIC |
12.55% | 14.19% | 11.58% | 13.12% | |
Accounts Receivable Turnover |
6.31 | 6.47 | 6.36 | 6.49 | |
Accounts Payable Turnover |
8.47 | 9.60 | 9.26 | 10.82 | |
Inventory Turnover |
1.54 | 1.57 | 1.63 | 1.66 | |
Average Days of Payables |
40.63 | 33.17 | 34.10 | 37.13 | |
Days of Inventory on Hand |
221.40 | 218.78 | 204.64 | 202.14 | |
Tax Rate |
(0.23) | (0.23) | (0.24) | (0.26) | |
Research and Development Expense of Revenue |
4.92% | 4.83% | 4.48% | 4.42% | |
Selling, General and Administrative Expense of Revenue |
32.68% | 33.12% | 33.16% | 33.33% | |
Share Based Compensation of Revenue |
2.41% | 2.40% | 2.54% | 2.50% | |
Interest Coverage |
9.47 | 10.49 | 5.46 | 5.36 | |
Operating CF/Net income |
1.72 | 1.93 | 3.01 | 3.41 | |
Depreciation/Fixed assets |
0.43 | 0.41 | 0.38 | 0.37 | |
Capex/Depreciation |
(0.24) | (0.23) | (0.27) | (0.31) | |
Revenue per Share |
27.90 | 28.17 | 28.28 | 29.81 | |
Operating CF per Share |
6.07 | 7.24 | 6.22 | 7.23 | |
Capex per Share |
(0.63) | (0.59) | (0.67) | (0.79) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 |
Columns are period end dates